Lee Peter Hartner MD
Gastrointestinal Cancer, Head & Neck Cancer, Hematologic Oncology, Sarcoma
Assistant Clinical Professor of Medicine, University Pennsylvania
Join to View Full Profile
230 W Washington Sq2nd FloorPhiladelphia, PA 19106
Phone+1 215-829-6088
Fax+1 215-829-6104
Dr. Hartner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Tufts University School of MedicineClass of 1994
Certifications & Licensure
PA State Medical License 2004 - 2026
MA State Medical License 2001 - 2006
CT State Medical License 2000 - 2002
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
- Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
- Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsSafety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC...Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner
Lancet. 2024-11-23 - 2 citationsOnset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.Elizabeth T Loggers, Rashmi Chugh, Noah Federman, Lee Hartner, Richard F Riedel
Cancer. 2024-08-15 - 68 citationsNirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.Mrinal Gounder, Ravin Ratan, Thierry Alcindor, Patrick Schöffski, Winette T van der Graaf
The New England Journal of Medicine. 2023-03-09
Professional Memberships
- Member
- Member
- Connective Tissue Oncology SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
